Is Werfen profitable in 2025?

Yes, but margins shrank. Werfen's FY2025 net profit was €144 million, down 15% year over year from €170 million in FY2024, on revenue of €2.131 billion, a decline the company attributed explicitly to US-EU tariffs (reported 2026-04-09/20).

Werfen is privately held and family-owned by the Rubiralta family, who founded it in 1966 in Barcelona as distributor Izasa. It is not publicly traded, though it issued a €500 million 7-year bond in 2025 while keeping an investment-grade rating.

Could AI replace Werfen?

No. Werfen's core business is FDA/CE-cleared diagnostic hardware, reagents and hospital LIS integration across tens of thousands of installed analyzers; AI cannot manufacture or gain regulatory clearance for physical IVD devices, though peripheral data-management software is more exposed.

Is Werfen a safe company to join?

Werfen is a 60-year-old, profitable oligopoly player with about 7,000 employees globally, but FY2025 job postings fell 18.2% amid tariff-driven margin pressure that cut net profit 15% to €144 million (2026-04-09).

Who is Werfen's biggest competitor?

Werfen competes in a five-player hemostasis diagnostics oligopoly with Siemens Healthineers, Roche, Sysmex, and Diagnostica Stago; no single rival is reported taking share, and Werfen remains a top-5 global player as of 2025-2026.

Why did Werfen's profit fall in 2025?

Werfen's FY2025 net profit dropped 15% to €144 million despite revenue near €2.131 billion, because US-EU tariffs hit margins hard given roughly two thirds of its sales are generated in North America (reported 2026-04-09).

Biotech tools companies · Spain

Werfen S.A.

werfen.com ↗

Spanish maker of blood-testing and hemostasis machines used in hospitals worldwide.

Hard to displace

Assessed 24 July 2026 · Evidence as of 24 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 24 July 2026 · Checkable from Q1 2027 · Every call on the record Checkpoint: FY2026 results showing whether profit recovers from tariff hit

The call

Werfen's machines and reagents lock in hospitals in a way AI can't touch; the real pressure right now is US tariffs squeezing profit, not competitors or algorithms.

Werfen makes machines and test strips that hospitals use to check if blood clots properly. It is hard to replace because hospitals have thousands of its machines already installed, those machines only work with Werfen's test strips, and the company holds government approvals that new competitors cannot easily get. The biggest near-term danger is that tariffs between the US and Europe are shrinking the company's profits, and with €1.66 billion in debt, another year of shrinking profits could weaken its financial strength.

Why

AI pressure: None apparent. AI can't manufacture FDA/CE-cleared analyzers or reagents; it could only touch the data-software layer around Werfen's machines. Could AI do the core job? Unlikely.

Bigger players: Siemens Healthineers, Roche, Sysmex, Diagnostica Stago. Four other large players compete hard in the same hemostasis and diagnostics oligopoly, but none has visibly taken share from Werfen yet. Could a giant copy it? No, they are blocked.

What protects it. Tens of thousands of installed analyzers lock hospitals into Werfen's reagents, plus regulatory approvals rivals and AI can't skip.

What would change this call

Werfen FY2026 net profit figures released, showing recovery or further decline from FY2025's €144M. Indicates whether US-EU tariff pressure on margins is easing or worsening.
Werfen's credit rating reviewed by agencies against its €1.66B net debt. Shows whether deleveraging is on track or the debt structure is under strain.
Siemens Healthineers, Roche, or Abbott announce a new hemostasis or transplant diagnostics platform launch. Would show a named oligopoly rival visibly gaining ground in Werfen's core segments.

Key numbers

FY2025 revenue: €2.131 billion, +3.3% organic (2025)
FY2025 net profit fell 15% YoY to €144 million (2025)
Over 66% of sales come from North America (2025)

Named risks

US-EU tariffs cut FY2025 net profit 15 percent given roughly two thirds of sales are US-generated. Severity: high
Net financial debt of €1.661 billion against investment-grade rating requires sustained deleveraging in 2026. Severity: medium
Heavy North American revenue concentration exposes Werfen to future trade-policy shifts. Severity: medium
Family-ownership succession dynamics (Rubiralta family) create longer-term governance uncertainty. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Siemens Healthineers	contesting	Both hold share in hemostasis diagnostics oligopoly; Siemens claims 40+ years in segment (vendor-claimed)
Roche	contesting	Named peer in five-firm consolidated hemostasis/coagulation diagnostics market as of 2025-2026
Sysmex Corporation	contesting	Co-listed as top-5 hemostasis diagnostics player alongside Werfen, no share-loss evidence found
Diagnostica Stago	contesting	Closest direct hemostasis specialist peer, stable multi-decade oligopoly as of 2025

Questions people ask

Is Werfen profitable in 2025?: Yes, but margins shrank. Werfen's FY2025 net profit was €144 million, down 15% year over year from €170 million in FY2024, on revenue of €2.131 billion, a decline the company attributed explicitly to US-EU tariffs (reported 2026-04-09/20).
Who owns Werfen?: Werfen is privately held and family-owned by the Rubiralta family, who founded it in 1966 in Barcelona as distributor Izasa. It is not publicly traded, though it issued a €500 million 7-year bond in 2025 while keeping an investment-grade rating.
Could AI replace Werfen?: No. Werfen's core business is FDA/CE-cleared diagnostic hardware, reagents and hospital LIS integration across tens of thousands of installed analyzers; AI cannot manufacture or gain regulatory clearance for physical IVD devices, though peripheral data-management software is more exposed.
Is Werfen a safe company to join?: Werfen is a 60-year-old, profitable oligopoly player with about 7,000 employees globally, but FY2025 job postings fell 18.2% amid tariff-driven margin pressure that cut net profit 15% to €144 million (2026-04-09).
Who is Werfen's biggest competitor?: Werfen competes in a five-player hemostasis diagnostics oligopoly with Siemens Healthineers, Roche, Sysmex, and Diagnostica Stago; no single rival is reported taking share, and Werfen remains a top-5 global player as of 2025-2026.
Why did Werfen's profit fall in 2025?: Werfen's FY2025 net profit dropped 15% to €144 million despite revenue near €2.131 billion, because US-EU tariffs hit margins hard given roughly two thirds of its sales are generated in North America (reported 2026-04-09).

Timeline

2026-05-07Werfen and Oxford Nanopore announce strategic collaboration for transplant/HLA assays
2026-04-20Werfen reports FY2025 revenue €2.131B, 3.3% organic growth, issues €500M bond
2026-04-09Werfen FY2025 net profit falls 15% to €144M, cited tariffs as cause
2025-04-08Werfen reports FY2024 revenue €2.184B (+4%), net profit €170M
2024-10-16Werfen completes acquisition of Omixon for NGS transplant diagnostics
2024-07Werfen completes divestment of distribution businesses to Palex, over €100M
2023-03-15Werfen completes acquisition of Immucor for roughly US$2 billion
2021-07-12Werfen unifies all group companies under one brand name
2009Inova Diagnostics joins the Werfen group
1966Company founded in Barcelona as Izasa by Jose Maria Rubiralta

Revision history

24 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Merck KGaA (MilliporeSigma)Intertek Group plc Eurofins Scientific SE